<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004441</url>
  </required_header>
  <id_info>
    <org_study_id>HCCSC C02</org_study_id>
    <nct_id>NCT05004441</nct_id>
  </id_info>
  <brief_title>Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer</brief_title>
  <official_title>Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer：HCCSC C02 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhou Fuxiang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huangshi Central Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined&#xD;
      With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>36 months</time_frame>
    <description>Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>36 months</time_frame>
    <description>DCR was defined as the percentage of participants who have a confirmed complete response（CR） or partial response（PR） or stable disease（SD） per RECIST 1.1 as assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>OS is the time from enrollment to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (AE)</measure>
    <time_frame>36 months</time_frame>
    <description>overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>First-line treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First-line treatment: Fruquintinib Combined With mFOLFOX6/FOLFIRI for twelve cycles.&#xD;
Maintenance treatment: Fruquintinib and Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib Combined With mFOLFOX6/FOLFIRI</intervention_name>
    <description>Fruquintinib (3mg) will be given p.o. daily</description>
    <arm_group_label>First-line treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years, ≤75 years&#xD;
&#xD;
          2. Histologically confirmed unresectable or metastatic stage colorectal cancer&#xD;
&#xD;
          3. Known RAS activating mutation/wild type and BRAF wild type;&#xD;
&#xD;
          4. Patients have not received systematic treatment for unresectable or metastatic&#xD;
             colorectal cancer (those who have received adjuvant or neoadjuvant chemotherapy with&#xD;
             one regimen and relapsed more than 12 months after the end of chemotherapy can be&#xD;
             enrolled);&#xD;
&#xD;
          5. At least one measurable disease according to RECIST 1.1 guidelines for solid tumors；&#xD;
&#xD;
          6. BMI≥18；&#xD;
&#xD;
          7. ECOG 0-1&#xD;
&#xD;
          8. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          9. Patients must have adequate organ function&#xD;
&#xD;
         10. Women of childbearing age must have a negative pregnancy test within the first day of&#xD;
             the study, and contraceptive methods should be taken during the study until 6 months&#xD;
             after the last administration;&#xD;
&#xD;
         11. Informed consent has been signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received other systemic anti-tumor therapies within 2 weeks before&#xD;
             recruited(eg.chemotherapy or radiotherapy, immunotherapy, biological or hormonal&#xD;
             therapy, or any VEGFR inhibitor treatment);&#xD;
&#xD;
          2. Known BRAF activating mutation&#xD;
&#xD;
          3. systolic blood pressure &gt; 140mmHg or diastolic blood pressure &gt; 90mmHg regardless of&#xD;
             any antihypertensive drugs; Or patients need more than two antihypertensive drugs;&#xD;
&#xD;
          4. Clinically significant electrolyte abnormality;&#xD;
&#xD;
          5. Proteinuria ≥ 2+ (1.0g/24hr);&#xD;
&#xD;
          6. Patients have untreated central nervous system metastasis;&#xD;
&#xD;
          7. Patients have not recovered from all toxicities associated with prior anti-tumor&#xD;
             therapy ,to acceptable baseline status, or a National Cancer Institute Common&#xD;
             Terminology Criteria for Adverse Events(NCI CTCAE v5.0) Grade of 0 or 1, except for&#xD;
             alopecia and oxaliplatin induced neurotoxicity ≤ 2 , and the previous surgery did not&#xD;
             recover completely;&#xD;
&#xD;
          8. Have received other systemic anti-tumor therapies within 4 weeks before recruited;&#xD;
&#xD;
          9. Clinical uncontrolled active infections, such as acute pneumonia and active hepatitis&#xD;
             B / C (previous history of hepatitis B virus infection, whether drug controlled or&#xD;
             not, HBV DNA ≥ 104) × Copy number or ≥ 2000 IU / ml);&#xD;
&#xD;
         10. Dysphagia or known malabsorption of drugs;&#xD;
&#xD;
         11. Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in&#xD;
             GI;&#xD;
&#xD;
         12. Have evidence or history of bleeding tendency within 2 months after enrollment, the&#xD;
             researcher assessed that moderate or severe bleeding tendency was not suitable for&#xD;
             enrollment;&#xD;
&#xD;
         13. Stroke (including transient ischemic attack) occurred within 12 months before&#xD;
             admission;&#xD;
&#xD;
         14. Patients had other malignant tumors in the past 5 years or at the same time (except&#xD;
             for the cured skin basal cell carcinoma and cervical carcinoma in situ);&#xD;
&#xD;
         15. Pregnant or lactating women;&#xD;
&#xD;
         16. Allergic to fruquintinib；&#xD;
&#xD;
         17. History of immunodeficiency, including HIV positive, other acquired or congenital&#xD;
             immunodeficiency diseases, or organ transplantation;&#xD;
&#xD;
         18. Patients with acute myocardial infarction, severe / unstable angina pectoris or&#xD;
             coronary artery bypass grafting within 6 months before admission; Or a history of&#xD;
             arterial thrombosis or deep venous thrombosis;&#xD;
&#xD;
         19. There are concomitant diseases (such as severe hypertension, diabetes, thyroid&#xD;
             disease, active infection, etc.) that seriously endanger the safety of patients or&#xD;
             affect the completion of the study, or any laboratory abnormalities that are not&#xD;
             suitable for participating in the clinical trial according to the judgment of the&#xD;
             researcher,&#xD;
&#xD;
         20. Serious psychological or mental disorders that may affect the compliance study;&#xD;
&#xD;
         21. Participating in other drug clinical trials within 4 weeks before recruited.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fuxiang Zhou, M.D.</last_name>
    <phone>+86-027-67813155</phone>
    <email>happyzhoufx@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenbo Wang, M.D.</last_name>
    <phone>+86-027-67813215</phone>
    <email>wangwenbo@whu.edu.cb</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongnan Hopital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuxiang Zhou, M.D</last_name>
      <phone>+86-027-67813155</phone>
      <email>happyzhoufx@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhongnan Hospital</investigator_affiliation>
    <investigator_full_name>Zhou Fuxiang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

